Allergic rhinitis and asthma are common respiratory diseases. Qipian® is a Chinese medicine made from three types of bacteria, used to treat these conditions. This study will retrospectively analyze the effects of adding Qipian® to the regular treatment for patients with allergic rhinitis, with or without asthma. Patients meeting the Allergic Rhinitis and its Impact on Asthma（ARIA） and Global Initiative for Asthma（GINA） diagnostic criteria were divided into two groups: one receiving standard drug treatment, and the other receiving standard treatment plus Qipian®. The study will compare clinical symptoms and relevant blood markers before and after treatment to see if adding Qipian® leads to better outcomes than the standard treatment alone.This study aims to determine how Qipian® benefits patients with rhinitis and asthma and its effect on related serum indicators, helping to explore its role in allergic respiratory diseases.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Total Nasal Symptom Score (TNSS)
Timeframe: 12 weeks
Asthma Control Test（ACT）
Timeframe: 12 weeks
Concentration of immunoglobulin E (IgE)
Timeframe: 12 weeks
Concentration of immunoglobulin A (IgA)
Timeframe: 12 weeks
Concentration of immunoglobulin G (IgG)
Timeframe: 12 weeks
Concentration of Interleukin-4 (IL-4)
Timeframe: 12 weeks
Concentration of Interleukin-13 (IL-13)
Timeframe: 12 weeks
Concentration of Interleukin-10 (IL-10)
Timeframe: 12 weeks